ArticleBiomaterials research2025
Physicochemical Properties and Efficacy of Poloxamer Bone Wax on Hemostasis at the Bone-Amputation Site.
Article in Biomaterials research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Bone Marrow-Mimetic Hydrogel Enables Dual-Phase Hemostasis and Vascularized Osteogenesis for Cranial Defects.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone wax, an essential material for bone hemostasis in orthopedic, thoracic, and neurological surgeries, is defined as a substance that physically controls bleeding caused by bone fractures. Absorbable bone-wax products such as poloxamer multiblock copolymers can be topically applied, form a physical barrier, are biocompatible, and can be absorbed by/excreted from the body. However, absorbable bone waxes continue to have limited physical properties, poor bone adhesion, and low hemostatic quality. When applied to the affected area, they quickly dissolve in blood and body fluids, preventing maintenance of the physical barrier over a certain period and thereby reducing the hemostatic effect. This study introduces a new type of absorbable bone wax (OSSTOP) constructed from 2 poloxamer multiblock copolymers with different molecular weight ranges. To determine whether OSSTOP overcomes the limitations of the existing products, the physicochemical properties and efficacy of OSSTOP were compared with those of 2 existing absorbable bone-wax products, OSTENE and NOVOSEAL. The adhesive strengths, yield loads, and solubilities of the products were evaluated and compared in vitro. Hemostasis at the bone-amputation site and absorption/degradation of the products were then evaluated through animal experiments in vivo. The biological safety (cytotoxicity) of the newly developed OSSTOP was also assessed. A histological analysis confirmed superior hemostasis at the bone-amputation site and a favorable biological response after treatment with OSSTOP. We expect that OSSTOP will improve the convenience, hemostatic performance, and biocompatibility of bleeding cessation at bone-amputation sites in the clinical environment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.